139 related articles for article (PubMed ID: 37042954)
1. [Over one year of B‑cell targeted therapy with Ofatumumab s.c.: first results of a prospective, patient-centered real-world observational study].
Klimas R; Karl AS; Poser PL; Sgodzai M; Theile-Ochel S; Gisevius B; Faissner S; Nastos I; Gold R; Motte J
Nervenarzt; 2023 Oct; 94(10):923-933. PubMed ID: 37042954
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain.
Vudumula U; Patidar M; Gudala K; Karpf E; Adlard N
J Med Econ; 2023; 26(1):11-18. PubMed ID: 36472139
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Bar-Or A; Grove RA; Austin DJ; Tolson JM; VanMeter SA; Lewis EW; Derosier FJ; Lopez MC; Kavanagh ST; Miller AE; Sorensen PS
Neurology; 2018 May; 90(20):e1805-e1814. PubMed ID: 29695594
[TBL] [Abstract][Full Text] [Related]
4. To wait, or too late? Modeling the effects of delayed ofatumumab treatment in relapsing-remitting multiple sclerosis.
Montgomery SM; Green L; Karoui H; Nicholas R; Loh J
J Med Econ; 2023; 26(1):139-148. PubMed ID: 36546701
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis.
Kramer J; Linker R; Paling D; Czaplinski A; Hoffmann O; Yong VW; Barker N; Ross AP; Lucassen E; Gufran M; Hu X; Zielman R; Seifer G; Vermersch P
Mult Scler J Exp Transl Clin; 2023; 9(4):20552173231203816. PubMed ID: 37829441
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the treating physicians' first-hand experience with handling and satisfaction of ofatumumab therapy: findings from the PERITIA survey conducted in Europe.
Rau D; Eichau S; Borriello G; Cerqueira J; Wagner C
BMC Neurol; 2023 Apr; 23(1):147. PubMed ID: 37038104
[TBL] [Abstract][Full Text] [Related]
7. Intravenous ofatumumab treatment of multiple sclerosis and related disorders: An observational study.
El Mahdaoui S; Romme Christensen J; Magyari M; Wandall-Holm MF; Sellebjerg F
Mult Scler Relat Disord; 2022 Dec; 68():104246. PubMed ID: 36279600
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis.
Samjoo IA; Worthington E; Drudge C; Zhao M; Cameron C; Häring DA; Stoneman D; Klotz L; Adlard N
J Comp Eff Res; 2020 Dec; 9(18):1255-1274. PubMed ID: 33090003
[No Abstract] [Full Text] [Related]
9. COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.
Cross AH; Delgado S; Habek M; Davydovskaya M; Ward BJ; Cree BAC; Totolyan N; Pingili R; Mancione L; Hu X; Sullivan R; Su W; Zielman R; Gupta AD; Montalban X; Winthrop K
Neurol Ther; 2022 Jun; 11(2):741-758. PubMed ID: 35284994
[TBL] [Abstract][Full Text] [Related]
10. A Case of Prolonged Fever in a Patient Infected With COVID-19 on Ofatumumab.
Uddin Y; Ramirez H; Sheth MA
Cureus; 2023 Aug; 15(8):e43274. PubMed ID: 37692739
[TBL] [Abstract][Full Text] [Related]
11. Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab.
Craner M; Al Malik Y; Babtain FA; Alshamrani F; Alkhawajah MM; Alfugham N; Al-Yafeai RH; Aljarallah S; Makkawi S; Qureshi S; Ziehn M; Wahba H
Neurol Ther; 2022 Dec; 11(4):1457-1473. PubMed ID: 36048334
[TBL] [Abstract][Full Text] [Related]
12. Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.
Samjoo IA; Klotz L; Giovannoni G; Drudge C; Haltner A; Worthington E; Zhao M; Brennan R; Häring DA; Cameron C; Adlard N
Mult Scler Relat Disord; 2022 Oct; 66():104031. PubMed ID: 35841716
[TBL] [Abstract][Full Text] [Related]
13. Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
Hauser SL; Cross AH; Winthrop K; Wiendl H; Nicholas J; Meuth SG; Giacomini PS; Saccà F; Mancione L; Zielman R; Bagger M; Das Gupta A; Häring DA; Jehl V; Kieseier BC; Pingili R; Stoneman D; Su W; Willi R; Kappos L
Mult Scler; 2022 Sep; 28(10):1576-1590. PubMed ID: 35229668
[TBL] [Abstract][Full Text] [Related]
14. Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis.
von Essen MR; Hansen RH; Højgaard C; Ammitzbøll C; Wiendl H; Sellebjerg F
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35672145
[TBL] [Abstract][Full Text] [Related]
15. Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: Phase 2 APOLITOS study.
Kira JI; Nakahara J; Sazonov DV; Kurosawa T; Tsumiyama I; Willi R; Zalesak M; Pingili R; Häring DA; Ramanathan K; Kieseier BC; Merschhemke M; Su W; Saida T
Mult Scler; 2022 Jul; 28(8):1229-1238. PubMed ID: 34787005
[TBL] [Abstract][Full Text] [Related]
16. Ofatumumab and Early Immunological Cells Subset Characterization in Naïve Relapsing Multiple Sclerosis Patients: A Real-World Study.
D'Amico E; Zanghì A; Fantozzi R; Centonze D; Avolio C
Curr Neuropharmacol; 2023; 21(12):2563-2566. PubMed ID: 37534789
[TBL] [Abstract][Full Text] [Related]
17. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
Bar-Or A; Wiendl H; Montalban X; Alvarez E; Davydovskaya M; Delgado SR; Evdoshenko EP; Giedraitiene N; Gross-Paju K; Haldre S; Herrman CE; Izquierdo G; Karelis G; Leutmezer F; Mares M; Meca-Lallana JE; Mickeviciene D; Nicholas J; Robertson DS; Sazonov DV; Sharlin K; Sundaram B; Totolyan N; Vachova M; Valis M; Bagger M; Häring DA; Ludwig I; Willi R; Zalesak M; Su W; Merschhemke M; Fox EJ
Mult Scler; 2022 May; 28(6):910-924. PubMed ID: 34605319
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study.
Sorensen PS; Lisby S; Grove R; Derosier F; Shackelford S; Havrdova E; Drulovic J; Filippi M
Neurology; 2014 Feb; 82(7):573-81. PubMed ID: 24453078
[TBL] [Abstract][Full Text] [Related]
19. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
